Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer
- 1 January 1993
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 45 (2) , 10-19
- https://doi.org/10.2165/00003495-199300452-00004
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.1992
- Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.Journal of Clinical Oncology, 1991
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.Journal of Clinical Oncology, 1990
- Second malignancies after CMF for resectable breast cancer.Journal of Clinical Oncology, 1987
- Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.1986
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancerBreast Cancer Research and Treatment, 1985
- Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trialCancer, 1978
- Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancerCancer, 1978
- A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer.A southeastern cancer study group projectCancer, 1977